Abbott Laboratories (ABT)
NYSE · Healthcare · Medical - Devices
Profile
Abbott Laboratories
- Exchange
- NYSE
- Ticker
- ABT
- Sector
- Healthcare
- Industry
- Medical - Devices
- Country
- US
Abbott Laboratories, along with its affiliated entities, is a global healthcare enterprise dedicated to the research, development, manufacturing, and worldwide distribution of a diverse portfolio of health solutions. The company operates through four primary divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. In the Established Pharmaceutical Products segment, Abbott provides generic medications designed to treat a wide array of conditions, including pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorders, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine. This segment also supplies the anti-infective clarithromycin, influenza vaccines, and products aimed at regulating colon physiology. The Diagnostic Products division offers a comprehensive suite of diagnostic tools. These include laboratory systems for immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, as well as detect and quantify infectious agents. Additionally, this segment provides point-of-care systems, blood testing cartridges, rapid lateral flow testing products, and specialized molecular point-of-care tests for pathogens such as HIV, SARS-CoV-2, influenza A and B, RSV, and strep A. Its offerings also extend to cardiometabolic test systems, drug and alcohol screening solutions, remote patient monitoring, consumer self-test systems, and sophisticated informatics and automation solutions for laboratory use. The Nutritional Products segment is responsible for delivering nutritional formulations tailored for both pediatric and adult populations. Finally, the Medical Devices segment develops and commercializes rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular ailments. It also supplies diabetes care products and neuromodulation devices designed for the management of chronic pain and movement disorders. Founded in 1888, Abbott Laboratories maintains its corporate headquarters in North Chicago, Illinois.
Key facts
Abbott Laboratories: key facts
- Abbott Laboratories (NYSE: ABT) is a Medical - Devices company in the Healthcare sector.
- In fiscal 2025, Abbott Laboratories reported revenue of $44.3B and net income of $6.5B.
- Revenue grew 0.7% a year over the last 4 fiscal years.
- Free cash flow was positive in 5 of the last 5 fiscal years.
- Net income was positive in 5 of the last 5 fiscal years.
- Over the last twelve months, revenue was $48.2B and net income was $4.7B.
MonkScore
Abbott Laboratories's MonkScore
MonkScore
MonkScore range: 30–40
as of October 2026
Sector rank: 464 of 628 in Healthcare
How this score is madeDisclaimer
Pillar ranges
- Growth10–20
- Profitability40–50
- Quality20–30
- Market Conviction50–60
- Safety30–40
The MonkScore runs from 0 to 100. Each range is one of ten 10-point groups, from 0–10 to 90–100.
Each pillar's range uses the same ten groups. The exact score and the pillar scores are in the MonkStreet app.
Fundamentals
Figures from the statements
Abbott Laboratories's annual figures and the last twelve months, in USD. Last report: 30 September 2026.
| Figure | Last 12 months | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
| Revenue | $48.2B | $44.3B | $42.0B | $40.1B | $43.7B | $43.1B |
| Gross profit | $27.5B | $24.6B | $21.3B | $20.0B | $22.3B | $23.2B |
| Operating income | $7.4B | $8.0B | $6.8B | $6.4B | $8.4B | $9.2B |
| Net income | $4.7B | $6.5B | $13.4B | $5.7B | $6.9B | $7.1B |
| Operating cash flow | $9.9B | $9.6B | $8.6B | $7.3B | $9.6B | $10.5B |
| Capital expenditure | -$1.2B | -$2.2B | -$2.2B | -$2.2B | -$1.8B | -$1.9B |
| Free cash flow | $8.7B | $7.4B | $6.4B | $5.1B | $7.8B | $8.6B |
| Total debt | $32.6B | $15.1B | $15.3B | $15.9B | $17.9B | $19.3B |
| Cash | $5.1B | $8.5B | $7.6B | $6.9B | $9.9B | $9.8B |
Revenue growth a year
- 1-year
- 5.7%
- 3-year
- 0.5%
- 4-year
- 0.7%
Compound growth between fiscal years.
Peers
Similar companies
- CONMED CorporationNYSE:CNMDMonkScore range: 30–40
- Medtronic plcNYSE:MDTMonkScore range: 30–40
- Sight Sciences, Inc.NASDAQ:SGHTMonkScore range: 30–40
- Orthofix Medical Inc.NASDAQ:OFIXMonkScore range: 40–50
- Establishment Labs Holdings Inc.NASDAQ:ESTAMonkScore range: 40–50
- Boston Scientific CorporationNYSE:BSXMonkScore range: 40–50
- Tandem Diabetes Care, Inc.NASDAQ:TNDMMonkScore range: 40–50
- Butterfly Network, Inc.NYSE:BFLYMonkScore range: 50–60
Score my top stocks · 14-day free trial · card required · not charged during the trial · cancel in one click
MonkStreet provides research, not investment advice.
Page built on 31 October 2026.